Vedolizumab (Entyvio©) is a humanised IgG1 antibody which inhibits the action of the mucosal trafficking α4β7 integrin and prevents migration of inflammatory T cells to the gut. Vedolizumab levels are measured in serum taken from patients just before an infusion (trough) using an indirect ELISA coated with α4β7 integrin
For the monitoring of drug trough levels in IBD patients treated with Vedolizumab
|Results are reported between 0.8µg/ml and 96.0µg/ml. In the induction phase of the Entyvio© clinical trials week 6 trough levels were higher in responders than non-responders and higher trough levels were associated with increased mucosal healing in UC patients.|
Rust Top Vacutainer
Samples should be taken just before the next infusion of drug (trough)
Transportation at room temperature/ first class post is adequate. Storage at 4 degrees or -20 for long term.